genedx holdings corp - WGS

WGS

Close Chg Chg %
136.55 0.92 0.67%

Pre-Market

137.47

+0.92 (0.67%)

Volume: 295.93K

Last Updated:

Jan 8, 2026, 4:00 PM EDT

Company Overview: genedx holdings corp - WGS

WGS Key Data

Open

$136.74

Day Range

133.35 - 137.97

52 Week Range

55.17 - 170.87

Market Cap

$3.93B

Shares Outstanding

28.90M

Public Float

25.35M

Beta

2.07

Rev. Per Employee

N/A

P/E Ratio

2,180.76

EPS

$0.08

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

364.12K

 

WGS Performance

1 Week
 
4.99%
 
1 Month
 
-9.87%
 
3 Months
 
12.18%
 
1 Year
 
52.77%
 
5 Years
 
-63.54%
 

WGS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About genedx holdings corp - WGS

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

WGS At a Glance

GeneDx Holdings Corp.
North Tower
Stamford, Connecticut 06902
Phone 1-888-729-1206 Revenue 305.45M
Industry Medical/Nursing Services Net Income -52,286,000.00
Sector Health Services 2024 Sales Growth 50.79%
Fiscal Year-end 12 / 2025 Employees 1,000
View SEC Filings

WGS Valuation

P/E Current 2,180.763
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 6.767
Price to Book Ratio 8.78
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 4,152.546
Enterprise Value to Sales 6.689
Total Debt to Enterprise Value 0.057

WGS Efficiency

Revenue/Employee 305,450.00
Income Per Employee -52,286.00
Receivables Turnover 8.117
Total Asset Turnover 0.651

WGS Liquidity

Current Ratio 3.611
Quick Ratio 3.417
Cash Ratio 2.576

WGS Profitability

Gross Margin 57.781
Operating Margin -7.026
Pretax Margin -17.23
Net Margin -17.118
Return on Assets -11.144
Return on Equity -22.096
Return on Total Capital -14.419
Return on Invested Capital -14.902

WGS Capital Structure

Total Debt to Total Equity 47.862
Total Debt to Total Capital 32.369
Total Debt to Total Assets 25.259
Long-Term Debt to Equity 46.007
Long-Term Debt to Total Capital 31.115
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Genedx Holdings Corp - WGS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
212.19M 234.69M 202.57M 305.45M
Sales Growth
- +10.60% -13.69% +50.79%
Cost of Goods Sold (COGS) incl D&A
236.51M 289.43M 141.94M 128.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
23.36M 63.03M 35.83M 21.95M
Depreciation
23.36M 52.18M 19.71M 7.93M
Amortization of Intangibles
- 9.35M 14.03M 14.03M
COGS Growth
- +22.37% -50.96% -9.15%
Gross Income
(24.32M) (54.73M) 60.62M 176.49M
Gross Income Growth
- -125.09% +210.76% +191.13%
Gross Profit Margin
-11.46% -23.32% +29.93% +57.78%
2021 2022 2023 2024 5-year trend
SG&A Expense
416.34M 363.53M 217.06M 194.54M
Research & Development
99.34M 71.24M 51.56M 44.80M
Other SG&A
317.00M 292.29M 165.50M 149.75M
SGA Growth
+201,814.69% -12.68% -40.29% -10.37%
Other Operating Expense
- - 7.22M 3.41M
-
Unusual Expense
(192.91M) 179.16M 15.76M 15.12M
EBIT after Unusual Expense
(247.75M) (597.42M) (179.43M) (36.58M)
Non Operating Income/Expense
5.19M 2.60M 2.73M (13.01M)
Non-Operating Interest Income
- 79.00K 2.54M 1.11M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 2.83M 3.21M 3.03M
Interest Expense Growth
- - - +13.12%
-
Gross Interest Expense
- 2.83M 3.21M 3.03M
Interest Capitalized
- - - -
-
Pretax Income
(245.39M) (598.03M) (176.69M) (52.63M)
Pretax Income Growth
-127,545.08% -143.71% +70.45% +70.21%
Pretax Margin
-115.64% -254.81% -87.23% -17.23%
Income Tax
- (49.05M) (926.00K) (343.00K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- 72.00K 164.00K 241.00K
Income Tax - Deferred - Domestic
- (49.12M) (1.09M) (584.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(245.39M) (548.98M) (175.77M) (52.29M)
Minority Interest Expense
- - - -
-
Net Income
(245.39M) (548.98M) (175.77M) (52.29M)
Net Income Growth
-127,545.08% -123.72% +67.98% +70.25%
Net Margin Growth
-115.64% -233.91% -86.77% -17.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(245.39M) (548.98M) (175.77M) (52.29M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(245.39M) (548.98M) (175.77M) (52.29M)
EPS (Basic)
-74.9265 -53.6273 -7.2296 -1.9444
EPS (Basic) Growth
-65,337.99% +28.43% +86.52% +73.11%
Basic Shares Outstanding
3.28M 10.24M 24.31M 26.89M
EPS (Diluted)
-74.9265 -53.6273 -7.2296 -1.9444
EPS (Diluted) Growth
-65,337.99% +28.43% +86.52% +73.11%
Diluted Shares Outstanding
3.28M 10.24M 24.31M 26.89M
EBITDA
(417.29M) (355.23M) (127.83M) 492.00K
EBITDA Growth
-202,271.97% +14.87% +64.02% +100.38%
EBITDA Margin
-196.65% -151.36% -63.10% +0.16%

Snapshot

Average Recommendation BUY Average Target Price 169.778
Number of Ratings 9 Current Quarters Estimate -0.04
FY Report Date 03 / 2026 Current Year's Estimate 0.45
Last Quarter’s Earnings 0.09 Median PE on CY Estimate N/A
Year Ago Earnings 1.346 Next Fiscal Year Estimate 1.666
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 7
Mean Estimate -0.04 0.03 0.45 1.67
High Estimates 0.09 0.17 0.95 2.56
Low Estimate -0.39 -0.24 0.01 0.30
Coefficient of Variance -402.89 388.67 75.79 47.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Genedx Holdings Corp - WGS

Date Name Shares Transaction Value
Dec 12, 2025 Katherine A. Stueland CHIEF EXECUTIVE OFFICER; Director 9,983 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Katherine A. Stueland CHIEF EXECUTIVE OFFICER; Director 6,344 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $159.28 per share 1,010,472.32
Dec 12, 2025 Katherine A. Stueland CHIEF EXECUTIVE OFFICER; Director 26,186 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Kevin Feeley CHIEF FINANCIAL OFFICER 6,655 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Kevin Feeley CHIEF FINANCIAL OFFICER 5,389 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $159.28 per share 858,359.92
Dec 12, 2025 Kevin Feeley CHIEF FINANCIAL OFFICER 9,849 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 17, 2025 Bryan Michael DeChairo Chief Operating Officer 37,497 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Genedx Holdings Corp in the News